Abstract
: The outbreak of (SARS-CoV-2) originated in Wuhan, China, and pneumonia induced by this virus is named coronavirus disease 2019 (Covid-19). By March 29, 2020, 737000 people were infected and 35000 died worldwide. To date, no effective medication is recommended to treat SARS-CoV-2 infection, and the drugs introduced are still in the clinical trial phase. Tocilizumab and Remdisivir are possible drugs to treat and improve the symptoms of the patients. We prescribed a combination of Remdisivir and Tocilizumab to treat three critical patients with Covid-19, and presented the results in this article. After the duration of treatment with this combination, one case was improved and discharged, but, unfortunately, two cases expired.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
